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The pluripotent HEL cell line is frequently employed as an early megakaryoblastic model and can be induced to undergo differentiation toward the platelet progenitor megakaryocytic phenotype by cytokines, growth factors and phorbol esters, such as phorbol 12-myristate 13-acetate (PMA) [32] . Hence, given the critical role of prostacyclin-mediated signalling in platelets, the current study also sought to investigate the influence of phorbol ester-induced megakaryocytic differentiation of HEL cells on hIP gene expression. Herein, we have uncovered a novel mechanism of transcriptional repression and PMA-induction of PrmIPdirected gene expression that occurs through the regulated binding of C/EBPδ and PU.1 to the URR and of Sp1, PU.1 and Oct-1 to the core promoter region, respectively. These studies greatly advance understanding of the mechanisms of regulation of the hIP gene within the vasculature, including during megakaryocytic differentiation of the model platelet progenitor HEL cell line.
MATERIALS AND METHODS 2.1. Materials
Dual Luciferase® Reporter Assay System, pGL3Basic (PGL3B) and pRL-Thymidine Kinase (pRL-TK) were from Promega. DMRIE-C®, RPMI 1640 culture media and fetal bovine serum (FBS) were from Invitrogen. Anti-C/EBP (sc-150 X), anti-C/EBP (sc-636 X), anti-Sp1 (sc-59 X), anti-PU.1 (sc-22805 X), anti-Oct-1 (sc-232 X), normal rabbit IgG (sc-2027), goat anti-rabbit horseradish peroxidase (sc-2004) and mouse anti-goat horseradish peroxidase (sc-2354) were from Santa Cruz biotechnology. Anti-HDJ-2 (MS225 P1ABX) antibody was from Neomarkers.
Construction of luciferase-based genetic reporter plasmids
The plasmid pGL3B:PrmIP, encoding PrmIP (nucleotides -2449 to -772, relative to the translational start codon at +1) from the human IP gene in the pGL3B reporter vector, in addition to pGL3B:PrmIP1, pGL3B:PrmIP2, pGL3B:PrmIP3, pGL3B:PrmIP4, pGL3B:PrmIP5, pGL3B:PrmIP6 and pGL3B:PrmIP7 were previously described [31] .
Site-directed Mutagenesis
Site-directed mutagenesis (SDM) was carried out using the Quik-Change TM method (Agilent). The identities of the PrmIP elements subjected to SDM, with their starting positions in brackets, the nucleotides that were changed in underlined bold, templates used and names of the corresponding plasmids generated, as well as the identity, sequence and corresponding nucleotides of the specific primers used are listed below.
1. p53 (-1472) , from ggCATGTct to ggCATACct using template pGL3B:PrmIP4 to generate pGL3B:PrmIP4 p53* . Primers Kin 756 (5'-CAGGCTCGAGGGACTGGCATACCTCTCTCTGGCCAAGC -3') and complementary Kin 757. 2. PU.1 (-1454) , from ccTTCCtc to ccTTTCtc using template pGL3B:PrmIP4 to generate pGL3B:PrmIP4 PU.1(a)* . Primers Kin887 (5' -CTGGCCAAGCCTCCTTTCTCAGCTTTCTGGAAG-3' ) and complementary Kin888. 3 . STAT (-1433), from ctGGAAgg to ctAGCAgg using template pGL3B:PrmIP4 to generate pGL3B:PrmIP4 STAT* . Primers Kin837 (5' -CTCCTTCCTCAGCTTTCTAGCAGGAGTGAATTGTGTC -3' ) and complementary Kin838. 4 . PU.1 (-1375) , from gaGGAAtt to gaGGGAtt using template pGL3B:PrmIP4 to generate pGL3B:PrmIP4 PU.1(b)* , and using template pGL3B:PrmIP4 PU.1(a)* to generate pGL3B:PrmIP4 PU.1(a,b)* . Primers Kin889 (5' -CACTACATCAGAGAGGGATTTCCTGGTCATTTC -3' ) and complementary Kin890. 5. Nrf1 (-1356) , from tgGTCATtt to tgGTTGTtt using template pGL3B:PrmIP4 to generate pGL3B:PrmIP4 Nrf1* . Primers Kin833 (5' -CAGAGAGGAATTTCCTGGTTGTTTCTCAATCCCTGGGC-3' ) and complementary Kin834. 6 . NF B (-1359), from gaGGAATTTCCtg to gaGGACTTTCCtg using template pGL3B:PrmIP4 to generate pGL3B:PrmIP4 NF B(a)* . Primers Kin655 (5' -CACTACATCAGAGAGGACTTTCCTGGTCATTTCTC -3') and complementary Kin656. 7. NF B (-1363), from gaGGAATTTCCtg to gaGGAATCTCCtg using template pGL3B:PrmIP4 to generate pGL3B:PrmIP4 NF B(b)* . Primers Kin657 (5' -CACTACATCAGAGAGGAATCTCCTGGTCATTTCTC -3') and complementary Kin658. 8 . C/EBP (-1358), from tcTCAAtc to tcTCACtc using template pGL3B:PrmIP4 to generate pGL3B:PrmIP4 C/EBP* , using template pGL3B:PrmIP4 PU.1(a)* to generate pGL3B:PrmIP4 PU.1(a)*,C/EBP* and using template pGL3B:PrmIP4 PU.1(b)* to generate pGL3B:PrmIP4 PU.1(b)*,C/EBP* . Primers Kin891 (5' -CCTGGTCATTTCTCACTCCCTGGGCAATGT-3' ) and complementary Kin892. 9. C-LH (-1300), from gaATAGATcc to gaATATCTcc using template pGL3B:PrmIP4 to generate pGL3B:PrmIP4 C-LH* . Primers Kin831 (5' -GGGCCTGGAGCCCAGAATATCTCCCAGAGGCCACCCTGAGACAG -3' ) and complementary Kin832.
The plasmids pGL3B:PrmIP6 Sp1* , pGL3B:PrmIP6 PU.1* , pGL3B:PrmIP6 Oct-1* , pGL3B:PrmIP6 Sp1*,PU.1* , pGL3B:PrmIP6 Sp1*,Oct-1* , pGL3B:PrmIP6 PU.1*,Oct-1* and pGL3B:PrmIP6 Sp1*,PU.1*,Oct-1* were previously described [31] .
Cell Culture
Human erythroleukemic (HEL) 92.1.7 cells, obtained from the American Type Culture Collection, were cultured in RPMI 1640, 10 % FBS. Cells were grown at 37 o C in a humid environment with 5 % CO 2 and were confirmed to be free of mycoplasma contamination.
Luciferase-based Genetic Reporter Assays
Human erythroleukemic (HEL) 92.1.7 cells were co-transfected with the various pGL3B-recombinant plasmids, encoding firefly luciferase, along with pRL-TK, encoding renilla luciferase, using DMRIE-C® transfection reagent as previously described [33] . In the case of PMA treatments, the medium was supplemented with PMA (100 nM) or, as a control, with vehicle (0.1% (v/v) DMSO) ~24 h post-transfection and cells were incubated for a further 24 h before harvesting. Cells were then assayed for firefly and renilla luciferase activities using the Dual-Luciferase Reporter Assay System TM , and luciferase activities were calculated as a ratio (firefly:renilla luciferase) and expressed in relative luciferase units (RLU) [33] .
To investigate the effect of over-expression of C/EBP , C/EBP and PU.1 on PrmIP-directed gene expression, HEL cells were co-transfected with pGL3B:PrmIP4 (1.5µg) and 30ng of pRL-TK along with either pCMV5:C/EBP , pCMV5:C/EBP or pCMV5:PU.1 or, as a control, pCMV5 (1µg). Cells were harvested 48 h post-transfection and assayed for luciferase activity, as described before. pCMV5:C/EBP , encoding the full length cDNA for C/EBPβ was obtained from ImaGenes (Clone IMAGp998D1710064Q). pCMV5:PU.1, encoding full length PU.1 was from GeneService LTD (Clone number 5210783). pCMV5:C/EBP [34] was generously donated by Professor A-Mei Huang, Kaohsiung Medical University (Kaohsiung, Taiwan).
A gene reporter assay was performed to investigate changes in intracellular cAMP levels in response to stimulation of the hIP with its selective agonist cicaprost, using the method previously described [15] . In brief, the medium was supplemented with PMA (100 nM), or, as a control, with vehicle (0.1% (v/v) DMSO) ~24 h post-transfection. Cells were treated 48 h after transfection with IBMX (100 M) at 37 °C for 30 min and then stimulated with either vehicle (V; DMSO) or 1 M cicaprost at 37 °C for 3 h before harvesting. Firefly and Renilla luciferase activities were assayed 52 h after transfection using the Dual Luciferase Assay System® and expressed as a ratio (RLU).
Real-time PCR analysis:
Total RNA was isolated using TRIzol reagent (Invitrogen) from HEL cells (5 x 10 6 approximately). In the case of PMA treatment, cells were preincubated for 24h with PMA (100 nM) or, as a control, with vehicle [0.1% (v ⁄ v) DMSO]. DNase I-treated total RNA was converted to first-strand (1°) DNA with M-MLV reverse transcriptase (Promega). Real-time quantitative (QT) -PCR analysis was then performed, using the SyBr green reaction kit (Promega), with primers designed to specifically amplify hIP mRNA sequences (forward, 5'-GAAGGCACAGACGCACGGGA-3', Nu -57 to -37 of Exon 1; Kin264; reverse, 5'-GGCGAAGGCGAAGGCATCGC -3'; Nu 294 to 275 of Exon 2; Kin266) to generate a 348 bp amplicon or, as an internal control, using primers designed to amplify a 588bp region of the human 18s rRNA gene (forward, 5'-CGGCTACCACATCCAAGGAA-3'; reverse, 5'-TCGTCTTCGAACCTCCGACT-3'). The levels of hIP mRNA were normalized using corresponding 18s rRNA expression levels, to obtain Ct values. Relative IP mRNA expression levels were then calculated using the formula 2 -Ct [35] , and data is presented as mean changes in hIP mRNA expression in over-expressed or PMA-treated cells relative to those levels in control transfected (pCMV5) or vehicle-treated (0.1% (v ⁄ v) DMSO) cells, set to a value of 1 (Relative expression ± SEM, n = 3).
Immunoblot Analysis
Detection of endogenous or ectopically expressed C/EBP , C/EBP , PU.1, Sp1 and Oct-1 proteins in HEL cells was confirmed by immunoblot analysis. Briefly, whole cell protein from HEL cells or HEL cells transiently co-transfected with pCMV5:C/EBP , pCMV5:C/EBP or pCMV5:PU.1 or, as a control, with pCMV5 (50µg per lane) were resolved by SDS-PAGE (10 % acrylamide gels) and transferred to polyvinylidene difluoride (PVDF) membrane according to standard methodology. Membranes were screened using anti-C/EBP , anti-C/EBP , anti-PU.1, anti-Sp1 and anti-Oct-1 sera in 5 % non-fat dried milk in 1 x TBS (0.01 M Tris-HCl, 0.1 M NaCl) overnight at 4°C followed by washing and screening using either goat anti-rabbit horseradish peroxidise (sc-2004) or mouse anti-goat horseradish peroxidise (sc-2354) followed by chemiluminescence detection. To confirm uniform protein loading in each case, the blots were stripped and rescreened with anti-HDJ-2 antibody (Neomarkers) to detect endogenous HDJ-2 protein expression which served as an additional protein loading control.
Chromatin Immunoprecipitation (ChIP) Assays
ChIP assays were performed in HEL cells as previously described [36] . Briefly, HEL cells (1 x 10 8 ) were grown in RPMI, 10 % FBS to 70 % confluency and collected by centrifugation at 2,000 g for 5 min at 4 o C, washed twice in ice-cold PBS and resuspended in 50 ml serum-free RPMI. For PMA treatments, cells were pre-incubated with PMA (100 nM for 0, 5, 8, 16 and 24 h). Formaldehyde (1 %)-cross linked chromatin was sonicated to generate fragments ranging from 350 bp to 1000 bp in size, as illustrated in Supplemental Fig.  1A ). Sheared chromatin was resuspended in a final volume of 6 ml lysis buffer. Prior to immunoprecipitation, chromatin was incubated with 40 g normal rabbit IgG overnight at 4 o C on a rotisserie, after which 250 l of salmon sperm DNA/protein A agarose beads (Millipore) were added and chromatin was precleared overnight at 4 o C with rotation. Thereafter, for chromatin immunoprecipitation (ChIP) assays, aliquots (672 µl) of the precleared chromatin were incubated with anti-C/EBP , anti-C/EBP anti-PU.1, anti-Sp1, anti-Oct-1 (10 g aliquots in all cases) or, as controls, with normal rabbit IgG (10 g) antibodies or in the absence of primary (1°) antibody (-AB). Aliquots (270 µl) were stored for use as input chromatin DNA. All antibodies used for ChIP analysis were ChIP validated by the supplier (Santa Cruz) and have been used previously for such analyses [31, [36] [37] [38] [39] [40] . Following elution of the immune complexes from the beads, formaldehyde cross-links were reversed by incubation at 65 o C overnight followed by protease digestion with proteinase K (Gibco-BRL #25530-031; 9 l of 10 mg/ml) at 45 o C for 7 h. After precipitation, samples were resuspended in 50 l dH 2 O. PCR analysis was carried out using 2-3 l of ChIP sample as template or, as a positive control, with an equivalent volume of a 1:4 dilution of the input chromatin DNA. The identities of the primers used for the ChIP PCR reactions, as well as their sequences and corresponding nucleotides within PrmIP are listed below.
1. Kin 1286: 5'-TCGGGTCTCTGCAGGGTGAGCTGGGTGC-3', Nu -1556 to -1528 2. Kin 1287: 5'-GCCTGGGCTGTCTCAGGGTGGCCTCTGG -3', Nu -1327 to -1299 3. Kin538: 5'-GAGA GGTACC ACCCTGAGACAGCCCAGG-3', Nu -1291 to -1263 4. Kin274: 5'-CTCTCAAGCTTCTCTCCAGTCTTGCCCAGGCTC -3' , Nu -827 to -794 5. Kin 534: 5'-GAGAGGTACCCAGCGGTGGTGGCTTGGCTGTG -3' , Nu -1783 to -1761 6. Kin 677: 5'-CTCTAAGCTTGGAGACTTCCATGGC -3' , Nu -1577 to -1562 7. Kin 364: 5'-TTGGGTCCAGAAGGTCGAGGC3 -3', Nu -1081 to -1061 8. Kin 365: 5'-GCGAACCAGGGCGAGGC -3' , Nu -711 to -695
For quantitation of the relative abundance of the PCR products derived from the individual test or control immunoprecipitates relative to that of the products derived from the respective input chromatins, real-time QT-PCR reactions were carried out for the same number of cycles (typically 35 cycles) using the Agilent MX3005P QPCR system to obtain cycle threshold (Ct) values. Changes in relative PCR product intensities were then calculated using the Relative Quantification method using the formula 2 -Ct [35] . Data is presented as mean product intensities of the individual test or control immunoprecipitates expressed as a percentage relative to those derived from the corresponding input chromatins. For all ChIP-based experiments, PCR (semi-quantitative and real time QT-PCR) data presented is obtained from at least 3 independent ChIP immunoprecipitations using chromatin extracted on at least 3 occasions, rather than from triplicate PCRs using chromatin precipitated from single ChIP experiments.
Statistical analysis
Statistical analyses of differences were carried out using the unpaired Student' s t test or two-way ANOVA followed by post hoc Dunnett' s multiple comparison t tests, employing GraphPad Prism, version 4.00 package. All values are expressed as mean ± standard error of the mean (SEM). P-values of less than or equal to 0.05 were considered to indicate a statistically significant difference. To investigate overall differences between time-dependent increases in PrmIP-and PrmIP4-directed luciferase expression, nonlinear regression (R 2 ) and F-test analyses were carried out, where P-values of the slopes were greater than 0.05 and considered not to indicate a statistically significant difference. As relevant, *, **, *** and **** indicate p 0.05, 0.01, 0.001 and 0.0001, respectively.
RESULTS: 3.1. Identification of an upstream repressor region (URR) within PrmIP
Prostacyclin primarily signals through its specific cell surface prostacyclin receptor, or IP, and plays a central role in haemostasis and in vascular repair control of its regulatory promoter, herein referred located upstream of the translation initiation codon within the hIP gene ( Fig 1A) . In recent studies aimed at identifying the factors that regulate hIP gene expression within the vasculature, including in the model megakaryoblastic HEL 92.1.7 cell line, it was Sp1, PU.1 and Oct-1 through their binding to 917 [31] , as illustrated in Fig 8A. In a follow up study, directly regulated by estrogen through a transcriptional mechanism involving the direct binding of the estrogen receptor (ER) , but not ER , to a highly conserved upstream estrogen response element (ERE) located at approximately -1676 [15] ( Fig 8A) region (URR) within PrmIP, betweenfactors that regulate the URR remain to be investigated to further investigate the factors regulating hIP gene expression in HEL cells by identifying the factors that bind and regulate the URR within PrmI Initially, and consistent with previous findings genetic reporter assays confirmed the presence of the URR located between ( Fig 1A) . Specifically, 5' deletion of nucleotides from PrmIP4 ( 1.7-fold increase in luciferase expression (P < 0.0001). Bioinfomatic analysis of PrmIP several cis-acting elements within the putative URR, including 2 PU.1 b PU.1(b) at -1454 and -1375, respectively, and a C/EBP site at (SDM) in conjunction with genetic reporter assays established that disruption of the PU.1(b) and C/EBP sites individually led to 1.4-and 1.3-fold increases in PrmIP 0.0004) respectively, while mutation of the PU.1( fold; P = 0.0065). On the other hand, SDM of the various other predicted elements within the putative did not significantly affect PrmIP-directed luciferase expression ( Fig 1B) .
Combined disruption of the PU.1(a) and PU.1(b) induced luciferase expression (P = 0.0002) site alone. On the other hand, disruption of the alleviated repression resulting in a 1.6levels that were not substantially different to those significant difference between the effect of to disruption of all PU.1(a), PU.1(b) and C/EBP elements disruption of the PU.1(a) and C/EBP elements did not substantially affect PrmIP4 expression relative to mutating the C/EBP element alone (P = 0.1015). identified a major URR within PrmIP and established that repression in this region is largely mediated by transcription factor binding to the putative but that the PU.1(a) element at -1454 may only play a minor role, if any.
Characterisation of functional PU.1 and C/EBP
The CCAAT/enhancer binding proteins (C/EBPs) are a family of 6 transcription factors (C/EBP C/EBPP ) containing a highly conserved C dimerization and DNA binding [42] , where C/EBP and C/EBP associated genes, including COX-2, peroxisome proliferator growth factor-receptor [43] [44] [45] [46] . PU.1, a transcription factor been previously confirmed to be the only member of the Ets family to bind to the core region of PrmIP to regulate basal hIP gene expression [31] to the URR of the PrmIP in vivo, chromatin immunoprecipitation (ChIP) assays were carried out using chromatin extracted from HEL cells and antibodies specific to endogenous PU.1, C/EBP an general, the fragment size of the sheared chromatin DNA used in the ChIP studies range bp and, for all ChIP studies, PCR amplicons generated analysed by agarose gel electrophoresis ( PCR analysis using primers specific to the the anti-C/EBP and, to a lesser extent, from the amplicons were also generated from the input chromatin, but not from the Keating GL et al., BBA (GRM), (2012),
Identification of an upstream repressor region (URR) within PrmIP
Prostacyclin primarily signals through its specific cell surface prostacyclin receptor, or IP, and plays a central role in haemostasis and in vascular repair [1, 2, 4, 5, 13, 14] . In humans, expression of the hIP is under the control of its regulatory promoter, herein referred to as the PrmIP and defined as nucleotides d upstream of the translation initiation codon within the hIP gene ( Fig 1A) . In recent studies aimed at identifying the factors that regulate hIP gene expression within the vasculature, including in the model megakaryoblastic HEL 92.1.7 cell line, it was established that its expression is transcriptionally regulated by 1 through their binding to cis-acting elements within the core PrmIP region at . In a follow up study, it was also established that hIP gene directly regulated by estrogen through a transcriptional mechanism involving the direct binding of the , but not ER , to a highly conserved upstream estrogen response element (ERE) ( Fig 8A) . While the former study also revealed an upstream repressor -1524 to -1293, the identity of the cis-acting elements or factors that regulate the URR remain to be investigated [31] . Hence, the initial aim of the current study was to further investigate the factors regulating hIP gene expression in HEL cells by identifying the factors that bind and regulate the URR within PrmIP.
Initially, and consistent with previous findings [31] , 5' deletional analysis and luciferase genetic reporter assays confirmed the presence of the URR located between -1524 to -1293 within PrmIP ( Fig 1A) . Specifically, 5' deletion of nucleotides from PrmIP4 (-1524) to generate PrmIP5 ( fold increase in luciferase expression (P < 0.0001). Bioinfomatic analysis of PrmIP acting elements within the putative URR, including 2 PU.1 binding sites, designated PU.1 1375, respectively, and a C/EBP site at -1358 ( Fig 1B) . Site-directed mutagenesis (SDM) in conjunction with genetic reporter assays established that disruption of the PU.1(b) and C/EBP sites fold increases in PrmIP-directed luciferase activity (P = 0.0003 and P = 0.0004) respectively, while mutation of the PU.1(a) site yielded a more subtle, yet significant, increase (1.2 fold; P = 0.0065). On the other hand, SDM of the various other predicted elements within the putative directed luciferase expression ( Fig 1B) . Combined disruption of the PU.1(a) and PU.1(b) sites resulted in a 1.4-fold increase 002), to levels not substantially greater than disruption of the PU.1(b) disruption of the PU.1(b) and C/EBP elements together almost completely fold increase (P < 0.0001) in PrmIP4-directed luciferase expression to substantially different to those of PrmIP5 (P = 0.0946). It was notable that significant difference between the effect of combined disruption of the PU.1(b) and C/EBP and C/EBP elements together (P = 0.9559). Furthermore, combined disruption of the PU.1(a) and C/EBP elements did not substantially affect PrmIP4-directed luciferase expression relative to mutating the C/EBP element alone (P = 0.1015). Taken together, th identified a major URR within PrmIP and established that repression in this region is largely mediated by putative PU.1(b) and C/EBP elements at -1375 and -1358, respectively, may only play a minor role, if any.
Characterisation of functional PU.1 and C/EBP cis-acting elements within the URR
The CCAAT/enhancer binding proteins (C/EBPs) are a family of 6 transcription factors (C/EBP y conserved C-terminal basic leucine zipper (bZIP) domain involved in , where C/EBP and C/EBP regulate transcription of a number of CV 2, peroxisome proliferator-activated receptor and platelet . PU.1, a transcription factor essential for hematopoietic development, has been previously confirmed to be the only member of the Ets family to bind to the core region of PrmIP to [31] . Hence, to investigate if PU.1, C/EBP and/or C/EBP actually bind , chromatin immunoprecipitation (ChIP) assays were carried out using chromatin extracted from HEL cells and antibodies specific to endogenous PU.1, C/EBP an the fragment size of the sheared chromatin DNA used in the ChIP studies ranged amplicons generated from immune-precipitated chromatin DNA gel electrophoresis (e.g Fig 2A & 2B) and by real-time quantitative PCR ( PCR analysis using primers specific to the -1528 to -1327 region of PrmIP generated amplicons from C/EBP and, to a lesser extent, from the anti-PU.1 immunoprecipitates (Fig 2A & 2C (i) amplicons were also generated from the input chromatin, but not from the anti-C/EBP or the normal rabbit ., BBA (GRM), (2012), 1819, 428-445.
Prostacyclin primarily signals through its specific cell surface prostacyclin receptor, or IP, and plays a central . In humans, expression of the hIP is under the defined as nucleotides -2449 to -772 d upstream of the translation initiation codon within the hIP gene ( Fig 1A) . In recent studies aimed at identifying the factors that regulate hIP gene expression within the vasculature, including in the model its expression is transcriptionally regulated by acting elements within the core PrmIP region at -1042 togene expression is directly regulated by estrogen through a transcriptional mechanism involving the direct binding of the , but not ER , to a highly conserved upstream estrogen response element (ERE) . While the former study also revealed an upstream repressor acting elements or trans-acting . Hence, the initial aim of the current study was to further investigate the factors regulating hIP gene expression in HEL cells by identifying the trans-acting 5' deletional analysis and luciferase-based 1293 within PrmIP 1524) to generate PrmIP5 (-1293) yielded a fold increase in luciferase expression (P < 0.0001). Bioinfomatic analysis of PrmIP [41] predicted inding sites, designated PU.1(a) and directed mutagenesis (SDM) in conjunction with genetic reporter assays established that disruption of the PU.1(b) and C/EBP sites ted luciferase activity (P = 0.0003 and P = yet significant, increase (1.2fold; P = 0.0065). On the other hand, SDM of the various other predicted elements within the putative URR fold increase in PrmIP4greater than disruption of the PU.1(b) together almost completely directed luciferase expression to It was notable that there was no the PU.1(b) and C/EBP elements relative Furthermore, combined directed luciferase Taken together, these data have identified a major URR within PrmIP and established that repression in this region is largely mediated by 1358, respectively, acting elements within the URR The CCAAT/enhancer binding proteins (C/EBPs) are a family of 6 transcription factors (C/EBPterminal basic leucine zipper (bZIP) domain involved in regulate transcription of a number of CVand platelet-derived ntial for hematopoietic development, has been previously confirmed to be the only member of the Ets family to bind to the core region of PrmIP to Hence, to investigate if PU.1, C/EBP and/or C/EBP actually bind , chromatin immunoprecipitation (ChIP) assays were carried out using chromatin extracted from HEL cells and antibodies specific to endogenous PU.1, C/EBP and C/EBP . In d from 350 -1000 precipitated chromatin DNA were time quantitative PCR (e.g Fig 2C) . 1327 region of PrmIP generated amplicons from & 2C(i)). Specific C/EBP or the normal rabbit immunoglobulin G (IgG) immunoprecipitates or the no primary (1 o ) antibody control (-AB) ChIP assays ( Fig  2A & 2C(i) ). As an additional control of the specificity of C/EBP and PU.1 binding to the URR, PCR analysis using primers specific to an upstream region of PrmIP, spanning -1761 to -1577, generated amplicons from the input chromatin but not from the anti-C/EBP , anti-C/EBP , anti-PU.1, IgG immunoprecipitates or the no 1 o antibody controls, as illustrated by agarose gel electrophoresis data ( Fig 2B) . However, Real-time QT-PCR analysis of this data indicates that products were generated from anti-C/EBP , anti-C/EBP and anti-PU.1 immunoprecipitates in the -1761 to -1577 region, but their relative abundance is substantially reduced relative to those products derived from the -1528 to -1327 region (Fig 2C(ii) ). As a further negative control, QT-PCR analysis using primers which were previously described by us [47] and are specific to a region of Prm3 of the thromboxane receptor (TP) gene generated amplicons from the input chromatin but not from the anti-C/EBP , anti-C/EBP , anti-PU.1, IgG immunoprecipitates or the no 1 o antibody control (Supplemental Fig 1B(i) ). Endogenous expression of C/EBP , C/EBP and PU.1 in HEL cells was confirmed by immunoblot analysis, where secondary immunoblotting for the ubiquitously expressed HDJ-2 confirmed uniform protein loading ( Fig 2D (i-iii) ). Noteworthy, 3 separate forms of C/EBP referred to as LAP1 (46 kDA), LAP2 (41 kDa) and LIP (20 kDa) forms [42] were detected in HEL cells where the LIP form containing only the bZIP domain was the most abundant ( Fig 2D (i) ).
To further examine the possible role of C/EBP , C/EBP and PU.1 in the transcriptional regulation of PrmIP, the effect of their ectopic expression on hIP mRNA and PrmIP-directed reporter gene expression was investigated. Quantitative (QT) -PCR analysis confirmed that ectopic expression of C/EBP had no significant effect on hIP mRNA expression (P = 0.24), whereas C/EBP reduced (P = 0.013) and PU.1 increased (P = 0.03) its expression ( Fig 3A) . Similarly, ectopic expression of C/EBP did not significantly affect PrmIP-directed luciferase expression (P = 0.125), whereas C/EBP reduced (P < 0.0001) and PU.1 increased (P = 0.0009) its expression ( Fig 3B) . In all cases, immunoblot analysis confirmed over-expression of C/EBP , C/EBP and PU.1 in the transfected HEL cells ( Fig 3C ( 
Taken together, these data identify PU.1(b) and C/EBP as the critical cis-acting elements within the URR which mediate repression of PrmIP in HEL cells. ChIP data established that C/EBP , but not C/EBP , and to a lesser extent PU.1, binds within the URR of PrmIP in vivo. Furthermore, it was established that ectopic expression of C/EBP and PU.1 negatively and positively regulate hIP mRNA and gene expression, respectively, while C/EBP had no effect. Overall, it is proposed that along with C/EBP , PU.1 negatively regulates PrmIP transcription within the URR where PU.1(b) at -1375 and C/EBP at -1358 are the main cisacting elements involved.
Effect of PMA on IP expression in HEL cells: Identification of PMA-responsive region (PRR) 1 and PRR2 within PrmIP
It was also sought to investigate the influence of megakaryocyte differentiation on hIP gene expression following exposure of HEL cells to the phorbol ester PMA and, thereafter, to potentially identify the critical PMA responsive cis-acting element(s) within PrmIP. QT-PCR and luciferase-based gene reporter analyses established that PMA treatment (100 nM, 24 hr) significantly up-regulated IP mRNA expression (P = 0.0006; Fig 4A) and PrmIP-directed luciferase expression (P 0.0001; Fig 4B (i) ) but had no effect on pGL3B-directed luciferase expression (P = 0.79; Fig 4B (ii) ). As stated, the hIP is primarily coupled to Gsmediated adenylyl cyclase activation leading to agonist-dependent increases in cAMP generation [1, 10] . Thus, the effect of PMA treatment on the functional expression of the hIP in HEL cells was investigated by examining its effect on agonist-induced cAMP generation where cicaprost was used as the IP selective agonist. While stimulation of HEL cells with cicaprost led to a 2-fold increase in cAMP generation in vehicle -treated cells (0.1 % DMSO, 24 hr; P <0.0001), pre-incubation of cells with PMA (100nM, 24 hr) resulted in a 6.24-fold increase in cAMP generation (P < 0.0001; Fig 4C) .
Thereafter, 5' deletional analysis and genetic reporter assays were used to localize the main PMAresponsive regions within PrmIP (Fig 5A & 5B) . Pre-incubation of HEL cells with PMA resulted in a 1.85fold increase in PrmIP-directed luciferase expression (P 0.0001). Levels of PMA-induced luciferase expression directed by the successive 5' deletion subfragments PrmIP1 -PrmIP4 were not significantly different to that of PrmIP ( Fig 5A & 5B) . However, 5' deletion of nucleotides from PrmIP4 (-1524) to generate PrmIP5 (-1293) reduced the level of PMA-induced luciferase expression from 1.85-fold to 1.5-fold (P = 0.0002). While further 5' deletion of PrmIP5 (-1293) to PrmIP6 (-1042) had no effect on the PMAinduction, deletion of PrmIP6 to generate PrmIP7 (-917) almost completely abolished the PMA-induction (1.07-fold; P-value < 0.0001; Fig 5A & 5B) . These data establish that there are 2 PMA-responsive regions (PRRs) within PrmIP, where PRR1 is located between the subfragments PrmIP4 and PrmIP5 (-1524 to -1293) while PRR2 is between PrmIP6 and PrmIP7 (-1042 to -917) within the core promoter region [31] . To further validate that the main PMA responsive regions PRR1 and PRR2 are indeed localized downstream/3' of PrmIP4, the time course of PMA-induced luciferase reporter gene expression directed by PrmIP4 was compared with that directed by PrmIP (Fig 5C & 5D ). There was no significant difference between PMAinduced upregulation of PrmIP-and PrmIP4-directed luciferase expression (F-test analysis, P = 0.7007), confirming that all of the PMA responsive regions are found within PrmIP4.
Identification of the cis-acting PMA responsive elements within PRR1
As stated, the initial studies herein have established that hIP gene expression is subject to transcriptional repression through the binding of PU.1 and C/EBP to the PU.1(b) and C/EBP cis-acting elements of the URR identified between PrmIP4 (-1524) and PrmIP5 (-1293). Furthermore, it has also been established that the PRR1 also maps to the same region between PrmIP4 and PrmIP5. Hence, to further localize and/or identify the main cis-acting elements that mediate the PMA-responsive effect within PRR1, the effect of PMA-induced luciferase expression directed by the previously described mutated derivatives of PrmIP4 ( Fig  1B & 1C) were compared with that of wild type PrmIP4 (Fig 6A & 6B ; Supplemental Fig 2A & 2B) . As previous, while PMA treatment led to a 1.85-fold increase in PrmIP4-directed luciferase expression, specific mutation of the PU.1(a) and PU.1(b) elements, but not of the C/EBP or other putative cis-acting elements, within the overlapping PRR1/URR reduced the level of PMA-induction ( Fig 6A & 6B ; Supplemental Fig  2A & 2B) . More specifically, mutation of the PU.1(a) and PU.1(b) elements within PrmIP4 either individually (P = 0.0075 and P = 0.008, respectively) or collectively (P = 0.0005) reduced the PMAinduction from 1.85-fold to approximately 1.5-fold, while disruption of the C/EBP element either alone (P = 0.82) or in various combinations had no significant effect ( Fig 6A & 6B) . In fact, levels of PMA-induced luciferase expression by PrmIP4 carrying the mutated PU.1(a) or PU.1(b) elements, either alone or in combination, were not significantly different to those levels induced by the PrmIP5 subfragment which does not contain the PRR1 (P = 0.31). Collectively, these data establish that the PU.1(a) and PU.1(b) elements are the critical PMA-responsive cis-acting elements within PRR1. Furthermore, since the effect of disruption of the PU.1(a) and PU.1(b) elements alone was similar to their combined disruption, the data also suggests that binding of PU.1 at one of the sites (e.g to PU.1(a)) may depend on binding at the other site (e.g to PU.1(b)) or vice versa.
To investigate transcription factor binding to the over-lapping URR/PRR1 regions in vivo, as previous (Fig 2A) , ChIP analyses were carried out using antibodies directed to endogenous C/EBP , C/EBP and PU.1 and chromatin extracted from HEL cells following treatment with PMA for 0 -24 hr (0, 5, 10, 16 and 24 hr). Amplicons generated were either analysed by agarose gel electrophoresis ( Fig 6C & Fig 6D) or by real-time quantitative (QT) PCR ( Fig 6E( Fig 6F(i & ii) ). As expected, in all cases, primers surrounding the URR/PRR1 region generated amplicons from the input chromatin but not from anti-C/EBP immunoprecipitates or from the control assays (IgG immunoprecipitates or the no 1 o antibody control; Fig  6C & Fig 6E(i) ). Additionally, and consistent with previous data (Fig 2A) , at 0 hr, amplicons were generated from the anti-C/EBP immunoprecipitate and to a lesser extent from the anti-PU.1 immunoprecipitate. In contrast, at 5 hr, the relative abundance of the PRR1 amplicon generated from the anti-PU.1 immunoprecipitate was substantially increased while that from the anti-C/EBP immunoprecipitate was greatly diminished ( Fig 6C & Fig 6E(ii) ). At 10 hr, a PRR1 amplicon was generated from the anti-PU.1, but not from the anti-C/EBP immunoprecipitate and this pattern was sustained at 16 hr and 24 hr post-PMA treatment ( Fig 6C & 6E(iii-v) ). As an additional control for specificity, PCR analysis using primers specific to an upstream region of PrmIP, spanning -1761 to -1577, generated an amplicon from the input chromatin but not from the anti-C/EBP , anti-C/EBP , anti-PU.1 immunoprecipitates or the control ChIP assays regardless of the absence (0 hr) or presence (24hr) of PMA, as indicated by the agarose gel electrophoresis data ( Fig 6D) . As previous, real-time QT-PCR analysis of this data indicates that products were generated from anti-C/EBP , anti-C/EBP and anti-PU.1 immunoprecipitates in the -1761 to -1577 region, but their relative abundance is substantially reduced relative to products derived from the -1528 to -1327 region, in the absence or presence of PMA ( Fig 6F(i & ii) ). Also as previous, as a further negative control, QT-PCR analysis using primers specific to a region of Prm3 of the TP gene [47] generated amplicons from the input chromatin but not from the anti-C/EBP , anti-C/EBP , anti-PU.1, IgG immunoprecipitates or the no 1 o antibody controls (Supplemental Fig 1B(i & ii) ). In parallel with this, immunoblot analysis established that while the level of PU.1 expression in HEL cells was not altered following PMA treatment, the actual level of C/EBP expression was substantially reduced at 16 and 24 hr post-incubation ( Fig 6G & 6H) , while immunoblotting for the ubiquitously expressed HDJ-2 confirmed uniform protein loading ( Fig 6I) .
Collectively, these data establish that PU.1(a) and PU.1(b) are the critical cis-acting elements which contribute to the PMA-induction of hIP gene expression through the over-lapping URR/PRR1 identified herein within PrmIP. Additionally, through ChIP analyses it was established that under basal conditions, in the absence of PMA-induced HEL cell differentiation, C/EBP and to a lesser extent PU.1 bind to mediate repression of PrmIP-directed gene expression. However, in response to PMA induction of PrmIP-directed transcriptional expression, there is an overall switch from predominant C/EBP to PU.1 binding in this region, thereby converting the URR to a PRR1, which also coincides with a reduction in C/EBP protein expression whilst the level of PU.1 protein expression remains relatively unchanged.
Identification of the cis-acting PMA responsive elements within PRR2
As stated, it has been previously established that hIP gene expression is under basal regulation through the binding of Sp1, PU.1 and Oct-1 to functionally active cis-acting elements within the core promoter region (-1042 to -917) of PrmIP [31] . Furthermore, data herein also establish that the second PMA responsive region (PRR2) is also localized to this region (Fig 5A & 5B) . Hence, it was hypothesised that the Sp1, PU.1 and Oct-1 elements within the core promoter/PRR2 regions may contribute to the PMA-induced increase in PrmIP-directed gene expression. Treatment of HEL cells with PMA led to a 1.5-fold increase in PrmIP6-directed luciferase reporter gene expression ( Fig 7A & 7B) . While mutation of the Sp1, PU.1 and Oct-1 elements individually did not substantially affect the PMA-induction of PrmIP6 (P = 0.39, P = 0.96 and P = 0.41, respectively), disruption of all 3 elements together (P = 0.0004) and/or in certain double combinations only (Sp1 & Oct-1, P = 0.0041; PU.1 & Oct-1, P = 0.0044) almost completely abolished that induction ( Fig 7A & 7B) . Moreover, levels of PMA-induced luciferase expression directed by PrmIP6 carrying the mutated Sp1, PU.1 and Oct-1 elements in combination, were not significantly different to those levels directed by the PrmIP7 subfragment which does not contain the PRR2 (P = 0.1506).
Thereafter, ChIP analysis was used to investigate Sp1, PU.1 and Oct-1 binding to the PRR2 region of PrmIP in vivo following PMA-induced differentiation of HEL cells over a 0 -24 hr period (0, 5, 16 and 24 hr). As previous [31] , in the absence of PMA-treatment, primers surrounding the PRR2 region of PrmIP generated amplicons from the input chromatin and from the Sp1, PU.1 and Oct-1 immunoprecipitates but no PRR2 amplicons were generated from the control ChIP assays (0 hr; Fig 7C & 7E(i) ). Amplicons were also generated at 5, 16 and 24 hr post-PMA treatment, and the abundance of the products generated from the anti-Sp1, anti-PU.1 and anti-Oct-1 immunoprecipitates were relatively unchanged at 5 hr, but were each substantially increased at the latter time points (16 and 24 hr) suggestive of enhanced transcription factor binding to the chromatin in vivo in response to PMA-induced differentiation of HEL cells ( Fig 7C & 7E( iiiv)). In contrast, ChIP analysis using PCR primers specific to an upstream region of PrmIP, spanning -1761 to -1577, which is known not to be regulated by Sp1, PU.1 or Oct-1, did not generate amplicons from the anti-Sp1, anti-PU.1, anti-Oct-1 or control immunoprecipitates, regardless of the absence (0 hr) [31] or presence (24 hr) of PMA ( Fig 7D & 7F(i & ii) ). While we have previously established that the level of Sp1 expression is not affected by PMA-induced differentiation of HEL cells [37] , immunoblot analysis herein confirmed that the levels of PU.1 (Fig 6H) and Oct-1 ( Fig 7G) expression were also unaltered in response to PMA treatment.
Taken together, these data establish that the PMA-induced enhanced binding of Sp1, PU.1 and Oct-1 to their cis-acting elements within the core PrmIP6 region, which overlaps with the PRR2, contributes to the increased hIP gene expression that occurs during PMA-mediated differentiation of megakaryocytic HEL cells.
DISCUSSION
Within the vasculature, prostacyclin serves as a potent vasodilator and is the major inhibitory prostanoid in platelet aggregation [1] [2] [3] . The actions of prostacyclin generally oppose those of TXA 2 and alterations in the levels of TXA 2 and prostacyclin or of their specific synthases or their receptors (the TP and IP, respectively) have been implicated in a wide range of vascular disorders [4, [6] [7] [8] . Recent studies have shed significant new insights into how naturally occurring synonymous and non-synonymous SNPs within the coding sequence of the hIP contribute to propensity to CVD [28, 29, 48] . While SNPs also occur in the flanking regions of the hIP gene [30] , it is currently unknown whether SNPs within the hIP promoter may also contribute to population variations in hIP expression levels and/or to predisposition to CVD/CAD. The hIP promoter, herein termed PrmIP, has been defined as the region spanning nucleotides -2449 to -772 within the hIP genomic region, where the core promoter maps to -1042 to -917 and has been previously characterised [31] . That study also identified a major upstream repressor region (URR) between -1524 to -1293 (relative to the translation initiation codon at +1) and the initial aim of the current study was to identify the essential cis-acting elements and trans-acting factors which regulate PrmIP transcription within this region in the megakaryoblastic HEL 92.1.7 cell line.
Herein, bioinformatic analysis revealed the presence of nine potential cis-acting regulatory elements within the putative URR. Of those elements, only two were found to be functionally important within the URR under basal conditions, namely the PU.1(b) and C/EBP elements located at -1375 and -1358, respectively. More specifically in terms of the 2 putative PU.1 elements, as a role for the putative PU.1(a) element was only evident from the single mutational data, it is likely that it is less important than the PU.1(b) element and that binding of PU.1 to only one of the two putative PU.1 elements, namely to the PU.1(b) site, may be required to partner with C/EBPδ bound to the C/EBP element to mediate transcriptional repression. PU.1, encoded by the Spi1 gene in humans, is a member of the Ets family of transcription factors and has been reported to play a central role in hematopoeisis [49] . The importance of PU.1 in hematopoiesis is highlighted by the fact that deletion of the mouse equivalent of the Spi1 gene generates null mice with either fetal or perinatal lethality and multiple defects in blood cell development [50, 51] . As stated, PU.1 is the only member of the Ets family to bind within the core region of PrmIP to direct basal expression [31] . Moreover, PU.1 regulates gene expression by binding to canonical ETS motifs or to composite sites via interaction with other transcription factors such as interferon regulatory factor (Irf) 2, Irf4, Irf8, c-Jun and several members of the C/EBP family [52] [53] [54] [55] [56] [57] [58] . PU.1 activity can also be antagonized by interaction with members of the GATA family of transcription factors via a mechanism whereby PU.1 and GATA-1 co-exist on DNA to mutually repress gene expression [51] . Additionally, PU.1 can mediate transcriptional activation through interaction with acetyltransferases including CBP and p300 or repression by interacting with the deacetylases HDAC1, mSin3A and MeCP2 [59] .
As stated, the C/EBP family of transcription factors is composed of 6 members, C/EBP through to C/EBP [42] . They are so called because they interact with the CCAAT (cytidine-cytidine-adenosineadenosine-thymidine) box motif found in many, but not all, eukaryotic promoter sequences. C/EBP members bind to DNA as dimers, whereby they homo-or hetero-dimerise via their C-terminal leucine zipper domains, and are abundantly expressed to regulate diverse processes including energy metabolism, innate and adaptive immunity, inflammation, hematopoiesis, adipogenesis, osteoclastogensis, cell cycle, cellular proliferation and differentiation [40, 53, [60] [61] [62] [63] . C/EBP and C/EBP act synergistically to regulate transcription of various genes involved in immune and inflammatory responses [64] . Interestingly, the enzyme COX-2, primarily involved in prostanoid generation in response to inflammation, has been identified as a transcriptional target of both C/EBP and C/EBP [43] . C/EBP , along with cAMP response binding protein (CREB), plays a major role during the initial stage of COX-2 transcriptional activation, while C/EBP is subsequently recruited, along with the transcriptional co-activator p300 and several other factors, into a complex which regulates COX-2 transcription [43] . C/EBP and C/EBP are therefore critical transcriptional regulators of genes involved in prostanoid biosynthesis and function.
Herein, disruption of the PU.1(a), PU.1(b) and C/EBP elements individually within PrmIP led to modest increases in PrmIP4-directed luciferase expression, whereas disruption of the PU.1(b) and C/EBP elements in combination almost completely alleviated repression within the URR region. ChIP analyses indicated that C/EBP and to a lesser extent PU.1, but not C/EBP , are capable of binding within the URR region. Moreover, ectopic expression of C/EBP in HEL cells significantly reduced hIP mRNA and PrmIPdirected gene expression levels whereas, and consistent with previous findings [31] , PU.1 significantly increased expression levels while C/EBP had no effect. While PU.1 has been shown to positively regulate hIP gene expression through its binding to its cis-acting element within the proximal core PrmIP [31] , data generated herein suggest that under basal conditions C/EBP is predominantly bound to its cis-element within the URR and that it co-operates, or indeed may interact, with PU.1 to repress PrmIP gene expression. In fact, it has long been established that PU.1 can physically interact with C/EBP (NF-IL6β) through an interaction dependent on the C-terminal 28 AA residues of PU.1 and that they can simultaneously bind to adjacent DNA binding sites to synergistically influence the basal transcription complex [54] .
In light of the data presented herein and from our recent reports characterizing the PrmIP [15, 31] , we propose a model to explain the transcriptional regulation of the hIP gene, such as in megakaryocytic HEL cells ( Fig 8A) . It is proposed that PrmIP contains three spatially distinct regulatory domains; namely the estrogen-responsive region (ERR; -1783 to -1597), the URR described herein (-1524 to -1293) and the core regulatory region (-1042 to -917). In the context of the URR, it is proposed that C/EBP binds to its cisacting element and co-operates with PU.1 through its binding to the adjacent PU.1(b) element to repress the basal transcriptional apparatus. Interestingly, multi-sequence alignments confirmed that both the URR region and the PU.1(b) and C/EBP elements themselves are found within the PrmIP promoter regions from a range of other species (Fig 8B) , suggesting that this represents an evolutionary conserved mechanism of transcriptional regulation of the hIP gene. It is also noteworthy that the extent of overall identity between the human PrmIP and the IP promoter sequences from all other non-primates is low but that part of the URR, encompassing the PU.1(b) and C/EBP elements, represents the most highly conserved promoter region across all species examined ( Fig 8B & data not shown) .
As stated, the pluripotent HEL cell line is frequently employed as an early megakaryoblastic model and can be induced to undergo differentiation toward the platelet progenitor megakaryocytic phenotype by a range of agents including phorbol esters [32] . Furthermore, prostacyclin and its analogues have been shown to inhibit the differentiation process [65] . Hence, given the critical anti-thrombotic role of prostacyclin in regulating platelet activation status, it was also sought to examine the influence of PMA-mediated megakaryocyte differentiation on hIP gene expression in HEL cells. Data herein demonstrated substantial increases in hIP mRNA and gene expression in response to PMA-induced differentiation. Through deletional analysis, the PMA responsive regions were localised to 2 spatially distinct regions designated PRR1 and PRR2 which were found to co-localize/overlap with the URR and the previously characterized core PrmIP region [31] , respectively. Mutational analysis established that binding of PU.1 to the PU.1(a) and PU.1(b) sites, located at -1454 and -1375, respectively, mediates the PMA-induced increase in PrmIP activity within PRR1. Consistent with previous data herein, ChIP analyses reaffirmed that, under basal conditions and in the absence of PMA, C/EBP and, to a lesser extent, PU.1, but not C/EBP , preferentially bind to the URR/PRR1 region. However, in response to PMA-induction, C/EBP was gradually replaced by PU.1 leading to sustained PU.1 binding and transcriptional activation. Coincident with this, immunoblot analysis established that C/EBP expression was significantly reduced in a time-dependent manner in response to PMA treatment whilst PU.1 expression was unaffected. Overall, these data suggest that there is a switch in transcriptional regulator binding in vivo from predominantly C/EBP binding to the URR to predominantly PU.1 binding to the PMA-induced PRR1 region to enhance hIP gene expression and signalling in response to megakaryocyte differentiation. Consistent with this, C/EBP has been previously shown to bind to the COX-2 promoter, to regulate COX-2 expression under basal conditions in human foreskin fibroblasts. However, in response to PMA, C/EBP expression and binding to the COX-2 promoter were reduced and displaced by C/EBP [44] . The observation herein that the overall levels of PU.1 expression were unaltered in response to PMA treatment despite enhanced chromatin binding is also consistent with previous reports whereby it has been established that PMA-induced protein kinase (PK) C phosphorylation of PU.1 within its transactivation domain increases its binding capacity to a variety of PU.1 target genes [66, 67] . Hence, in the context of PrmIP, a model is presented in Fig 8C (i-ii) to illustrate the coordinated regulation of the PrmIP involving switching of nuclear factor binding of C/EBP to its cis-acting element, which mediates transcriptional repression under basal conditions, to binding of PU.1 to the PU.1(a) and PU.1(b) elements, to mediate transcriptional activation in response to PMA. It is proposed that as C/EBP expression and binding is decreased in response to PMA-induced differentiation, thereby lifting transcriptional repression and, consistent with previous data [66, 67] , that the phosphorylation status and binding capacity of PU.1 is increased, favouring transcriptional activation.
In PRR2, mutational analysis established that the Sp1, PU.1 and Oct-1 sites, located at -965, -952 and -947 respectively, function independently to mediate the PMA-induced increase in hIP gene expression in this region. Sp1, a member of the family of Sp1-like/KLF factors, serves as a key component of the eukaryotic transcriptional apparatus [68] . It has been previously established that Sp1 binds to a GC-rich element within the core region of PrmIP and that PU.1 and Oct1 are further recruited to drive basal expression of the hIP gene [31] (see also Fig 8A) . Oct-1 belongs to the Pit-Oct-Unc (POU) family of nuclear factors which bind to target sequences through their bipartite POU domains [69, 70] to regulate RNA polymerase II (POLII)-dependent transcription of various genes in conjunction with specific co-activators [71, 72] . ChIP analysis corroborated previous reports that Sp1, PU.1 and Oct-1 bind to the core PrmIP under basal conditions [31] but also established that, in all cases, binding of these factors to the chromatin in vivo was substantially increased in a time-dependent manner in response to PMA. Moreover, similar to PU.1 and Oct-1, we have previously established that expression of Sp1 is unaffected by PMA treatment of HEL cells [37] but its DNA binding affinity and capacity is enhanced due to PMA-induced ERK phosphorylation of Sp1 [73] [74] [75] In the case of Oct-1, while it has been implicated in mediating the PMA induction of the human-interleukin (IL)-5 gene promoter in the mouse EL4 T cell line [76] , the mechanism whereby phorbol esters increase Oct-1 binding to its target cis-acting DNA elements remains to be established. In the context of PrmIP, it is proposed that binding of Sp1, PU.1 and Oct-1 to the PRR2, which overlaps with the proximal core PrmIP region, is increased in response to PMA treatment of HEL cells, thereby further enhancing Sp1, PU.1 and Oct-1 regulation of the POLII-dependent transcription initiation apparatus (Fig 8C (iii) ).
In conclusion, it has been established that C/EBP is a critical transcriptional regulator of PrmIP which, along with PU.1, binds to the URR within PrmIP to repress transcription of the hIP gene in HEL cells under basal conditions. Additionally, PMA-mediated differentiation of HEL cells upregulates hIP mRNA and PrmIP-directed gene expression. The PMA responsiveness of PrmIP has been localised to 2 specific regions, referred to as PRR1 and PRR2 which overlap/co-localize with the URR and core PrmIP regions, respectively. PMA induction of PrmIP is mediated by a combined switch from (a) predominantly C/EBP binding to the URR under the repressed state to predominantly PU.1 binding to the PMA-activated PRR1, in addition to (b) PMA-induced enhanced binding of the Sp1, PU.1 and Oct-1 multi-component positive regulatory complex to the PRR2/core PrmIP region. It is possible that these findings in HEL cells are universal amongst all megakaryocyte cell lines, and may indeed be the case in other model cell lines, although this has not yet been established. Taken together, these data provide further critical insights into transcriptional regulation of the hIP gene and thereby provide a strong genetic basis for understanding the many diverse physiological functions of prostacyclin and the hIP, including its involvement in CVD/CAD.
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Characterisation of PRR1 within the PrmIP.
A , respectively, where mean levels of PCR product generated from the individual test or control immunoprecipitates expressed as a percentage relative to those levels derived from the corresponding input treated (100 nM, 5, 10, 16 or 24 hr) HEL cells. Panels G-I: ), as a loading control, HDJ2 expression following pretreated (100 nM; 5, 10, 16 and 24 hr) conditions. are representative of Panel A: Schematic of PrmIP composed of three major regulatory regions including the previously identified estrogen-reponsive element (ERE) where ER binds [15] , and a core regulatory region, where Sp1, PU.1 and Oct-1 bind to regulate basal transcription of the hIP gene [31] . Herein, an upstream repressor region (URR), located between -1524 and -1293, was revealed within PrmIP where C/EBP and PU.1 bind to mediate transcriptional repression of hIP gene expression. More specifically, it is proposed that coordinated binding of a dimeric C/EBP molecule to the cis-acting C/EBP element at -1358 and of PU. PrmIP5 or the various mutated -transfection, cells were incubated for an additional 24 hr with either vehicle (0.1% DMSO) or PMA (100 nM), prior to 4). In panel A, data is presented as relative luciferase induced luciferase activity. In A, the iferase activity relative to levels in vehicle-0.001 and 0.0001, respectively. As indicated in panel B, disruption of the indicated elements had no significant effect on the PMA response of PrmIP4.
